Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

SPC3649 Multiple Dose Study in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Santaris Pharma A/S Identifier:
First received: September 17, 2009
Last updated: October 4, 2011
Last verified: October 2011

September 17, 2009
October 4, 2011
September 2009
September 2010   (final data collection date for primary outcome measure)
Number of subjects experiencing adverse events [ Time Frame: Up to 169 Days ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00979927 on Archive Site
  • Peak Plasma Concentration (Cmax) of SPC3649 [ Time Frame: Up to 169 Days ] [ Designated as safety issue: No ]
  • Effect on total Cholesterol [ Time Frame: Up to 169 Days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
SPC3649 Multiple Dose Study in Healthy Volunteers
A Placebo-controlled Double-blind, Randomised, Multiple Dose, Dose Escalating Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649
The purpose of this study is to investigate the safety and tolerability of SPC3649 given in multiple doses to healthy volunteers.
Not Provided
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hepatitis C
  • Drug: SPC3649
    5 weekly doses
  • Drug: saline
    5 weekly doses
  • Placebo Comparator: Saline
    Intervention: Drug: saline
  • Active Comparator: SPC3649
    Intervention: Drug: SPC3649
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers: Males and postmenopausal females aged ≥ 18 to 60 years
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
SPC3649-202, Eudract no 2009-012153-38
Not Provided
Not Provided
Santaris Pharma A/S
Santaris Pharma A/S
Not Provided
Principal Investigator: Salah Hadi, MD,MSc PRA Health Sciences
Santaris Pharma A/S
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP